In this protocol, Dr, Sibai reviews the pathophysiology, diagnosis, and management of preeclampsia. Included are algorithms for management of mild hypertension-preeclampsia and severe preeclampsia.
As the author notes, women who develop preeclampsia in their first pregnancy are at increased risk (20%) for development of preeclampsia in subsequent pregnancies. With severe disease in a first pregnancy, the risk of recurrence is about 30%. With severe disease presenting in the second trimester, the risk of recurrent preeclampsia is 50%. There is an increased risk of chronic hypertension and undiagnosed renal disease, especially in patients with two episodes of severe preeclampsia in the second trimester. These patients should have adequate medical evaluation postpartum. There is also increased risk of intrauterine growth restriction in a subsequent pregnancy.
KEY MESSAGES:
Baha M. Sibai, MD University of Cincinnati College of Medicine, Ohio
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More